Skip to content
PeptideAgent

Cerebrolysin regulatory status

Current status of Cerebrolysin in the United States: Unscheduled. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What is the current status of Cerebrolysin?

Regulatory: UnscheduledWADA: Not WADA prohibitedVerified: Verified Sep 27, 2026
FDA and compounding
Cerebrolysin has never been submitted to or reviewed by FDA and is not an FDA approved drug. As an undefined biological mixture derived from animal brain it is not a bulk drug substance eligible for 503A or 503B compounding, and it has not been nominated to the 503A bulks list. It is a registered prescription drug in Austria (where it is manufactured), Russia, China, South Korea, and many other countries. Importing it for personal use in the United States is not lawful under FDA rules except in narrow circumstances that do not apply to routine use.
WADA
Not WADA prohibited
Access path
  1. Not legally available in the United States: no FDA approved product and no compounding pathway.
  2. Prescription in countries where it is registered (Austria, Russia, China, and others), administered by infusion in a clinic.
  3. Products imported or sold online for US use are not lawful and are not verified for cold chain or authenticity.

Full Cerebrolysin page: evidence, dosing in the literature, and sources

How has the status of Cerebrolysin changed over time?

No dated regulatory event has been recorded for Cerebrolysin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Cerebrolysin and the source of each dated event.

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  2. [2]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  3. [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  4. [4]WADA 2027 Prohibited List (published September 21, 2026, in force January 1, 2027)WADA, 2026